Quilt Bio secures £4m Series A

Focusing on experimental development within the biotech sector, Quilt Bio Limited has secured an estimated £4m Series A funding round. The company operates from Cambridge and specializes in bioinformatics, gene and RNA vectors, and nanobiotechnology. Its work extends to cell and tissue culture, protein engineering, and DNA analysis. Further activities include biology research involving various molecules and the use of process biotechnology techniques.

Incorporated in 2024, the business reported a £1.6m loss for the financial year ended 30 June 2025. During that period, the organization maintained a team of four employees.

This capital injection represents the total funding raised by the entity during 2026. Documentation for the allotment was filed in July.